Targeted Protein Degradation Comes of Age

This post is by Nello Mainolfi from LifeSciVC

Click here to view on the original site: Original Post

This blog was written by Nello Mainolfi, CSO and co-founder of Kymera Therapeutics, as part of the From The Trenches feature of LifeSciVC.

Translation of well validated biology into therapeutics remains one of the biggest challenges of modern drug development, in many cases due to lack of appropriate technologies to drug well credentialed biological targets. Examples in this category include driver oncogenes such as MYC, b-catenin and STAT3; catalytically active scaffolding kinases such as IRAK4 and RIPK’s or proteins whose accumulation is associated with well-established pathology such as alpha-synuclein in Parkinsons’s Disease or Tau in dementia and Alzheimer’s Disease.

Over the past decade, several new drug discovery technologies have been proven successful in overcoming some of the challenges of traditional small molecules therapeutics. One of the most successful modalities, therapeutic antibodies have allowed us to target cell surface and circulating proteins, very specifically, with high degree of affinity and most

Continue reading “Targeted Protein Degradation Comes of Age”